The lowest-dose, extended-cycle combined oral contraceptive pill with continuous ethinyl estradiol in the united states: A review of the literature on ethinyl estradiol 20 μg/levonorgestrel 100 μg + ethinyl estradiol 10 μg

Sheila Krishnan, Jessica W Kiley*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations

Abstract

Extended-cycle oral contraceptives (OCs) are increasing in popularity in the United States. A new extended-cycle OC that contains the lowest doses of ethinyl estradiol (EE) and levonorgestrel (LNG) + continuous EE throughout the cycle is now available. It provides 84 days of a low-dose, combined active pill containing levonorgestrel 100 μg and ethinyl estradiol 20 μg. Instead of 7 days of placebo following the active pills, the regimen delivers 7 days of ethinyl estradiol 10 μg. Existing studies reveal a similar efficacy and adverse effect profile compared with other extended-regimen OCs. Specifically, the unscheduled bleeding profile is similar to other extended-cycle OCs and improves with the increase in the duration of use. Although lower daily doses of hormonal exposure have potential benefit, to our knowledge, there are no published studies indicating that this specific regimen offers a lower incidence of hormone-related side effects or adverse events. In summary, this new extended-cycle OC provides patients a low-dose, extended-regimen OC option without sacrificing efficacy or tolerability.

Original languageEnglish (US)
Pages (from-to)235-239
Number of pages5
JournalInternational Journal of Women's Health
Volume2
Issue number1
StatePublished - Aug 18 2010

Keywords

  • Continuous regimen
  • Ethinyl estradiol
  • Extended cycle
  • Oral contraceptive

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology
  • Maternity and Midwifery

Fingerprint

Dive into the research topics of 'The lowest-dose, extended-cycle combined oral contraceptive pill with continuous ethinyl estradiol in the united states: A review of the literature on ethinyl estradiol 20 μg/levonorgestrel 100 μg + ethinyl estradiol 10 μg'. Together they form a unique fingerprint.

Cite this